www.accesswire.com Open in urlscan Pro
2606:4700:20::ac43:4322  Public Scan

Form analysis
0 forms found in the DOM

Text Content

This site uses cookies. By continuing to browse the site you are agreeing to our
use of cookies. Learn more
Got it!
Skip to main content

Enable accessibility for
visually impaired

Open the accessibility
menu

Open the Accessible
Navigation Menu







About
Who We Are Who We Serve
Services
Press Release Distribution Online Newsroom Platform id.
News
Resources
FAQ Sample Press Release Press Release Template Blog
Contact Login



Back to Newsroom


CUREVAC ANNOUNCES CHANGES OF CDO - MYRIAM MENDILA TO SUCCEED KLAUS EDVARDSEN

Wednesday, June 8, 2022 4:25 PM
CureVac
Visit Newsroom
Share this Article


Topic:
Management Changes
 * Myriam Mendila appointed as Chief Development Officer starting from February
   1, 2023
 * Klaus Edvardsen returning to Denmark after holding numerous leadership
   positions in the U.S. and Europe
 * Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as
   interim Chief Development Officer

TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V.
(NASDAQ:CVAC), a global biopharmaceutical company developing a new class of
transformative medicines based on messenger ribonucleic acid ("mRNA") today
announced that Chief Development Officer Klaus Edvardsen will leave the company
on June 30, 2022. He plans to return home to Denmark for a new professional
opportunity. CureVac is pleased to welcome Myriam Mendila to this key role.
Myriam's appointment will take effect on February 1, 2023. Until then, Ulrike
Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief
Development Officer.

"We would like to sincerely thank Klaus for his leadership across several
strategically decisive projects. We will miss his talents as Chief Development
Officer," said Jean Stéphenne, Chairman of CureVac's Board of Directors. CEO
Franz-Werner Haas added: "With his wealth of experience and expertise, Klaus has
been a great asset for the expansion of our pipeline, the development of our
technology platform and the growth of our company. We thank him for his
contributions to CureVac and wish him well for his next professional steps."

"With Myriam, we will continue our strong focus on oncology," continues Jean
Stéphenne. "I am convinced that her international leadership experience combined
with her expertise in building a broad product portfolio, especially in oncology
across different types of cancer, will be of significant importance as we expand
our pipeline and develop our organization."

"After having worked around the world for the past 20 years, I have decided it
is time for me to return home to Denmark," Klaus Edvardsen said. "It has been a
privilege to contribute to CureVac's progress in advancing mRNA as a key
technology, and I am confident the company will continue to make significant
progress on this journey. I would like to thank all of my colleagues at CureVac
and the Supervisory Board for their support and trust."

Myriam Mendila, MD has more than 20 years of global experience in product
development, medical affairs, pharmacovigilance and healthcare compliance as
well as global product strategy, including commercial strategy at Roche,
Genentech and Novartis. Over the last 5 years, she has held the position of
Worldwide Head of Medical Affairs and Chief Medical Officer Oncology at Novartis
Pharma AG, Switzerland where she drives and oversees the development and
cross-functional execution of the long-range global medical affairs vision and
strategy for the Novartis oncology portfolio. Myriam earned her medical degree
and subsequently doctoral degree from the Medical University of Hanover,
Germany.

Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology at CureVac, is
responsible for defining, building and executing CureVac's oncology strategy and
will serve as interim Chief Development Officer. Ulrike joined CureVac in 2011
as Head of Clinical Development and served as Chief Medical Officer from
2013-2019, before transitioning to her current role. Prior to joining CureVac,
Ulrike held positions as an oncologist at the National Center for Tumor Diseases
in Heidelberg and as Global Medical Leader at Merck KGaA, where she focused on
early clinical development of cancer vaccines and immune cytokines. Ulrike holds
a medical degree from the University of Homburg/Saar.

About CureVac

CureVac is a global biopharmaceutical company in the field of messenger RNA
(mRNA) technology, with more than 20 years of expertise in developing,
optimizing, and manufacturing this versatile biological molecule for medical
purposes. The principle of CureVac's proprietary technology is the use of
optimized mRNA as a data carrier to instruct the human body to produce its own
proteins capable of fighting a broad range of diseases. In July 2020, CureVac
entered in a collaboration with GSK to jointly develop new products in
prophylactic vaccines for infectious diseases based on CureVac's
second-generation mRNA technology. This collaboration was later extended to the
development of second-generation COVID-19 vaccine candidates, and modified mRNA
vaccine technologies. Based on its proprietary technology, CureVac has built a
deep clinical pipeline across the areas of prophylactic vaccines, cancer
therapies, antibody therapies, and the treatment of rare diseases. CureVac had
its initial public offering on the New York Nasdaq in August 2020. It is
headquartered in Tübingen, Germany, and employs more than 900 people at its
sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found
at www.curevac.com.

CureVac Investor Relations Contact

Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com

CureVac Media Contact

Bettina Jödicke-Braas, Manager Communications
CureVac, Tübingen, Germany
T: +49 7071 9883-1087
bettina.joedicke-braas@curevac.com

Forward-Looking Statements CureVac

This press release contains statements that constitute "forward looking
statements" as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the opinions,
expectations, beliefs, plans, objectives, assumptions or projections of CureVac
N.V. and/or its wholly owned subsidiaries CureVac AG, CureVac Real Estate GmbH,
CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH and CureVac RNA
Printer GmbH (the "company") regarding future events or future results, in
contrast with statements that reflect historical facts. Examples include
discussion of the potential efficacy of the company's vaccine and treatment
candidates and the company's strategies, financing plans, growth opportunities
and market growth. In some cases, you can identify such forward-looking
statements by terminology such as "anticipate," "intend," "believe," "estimate,"
"plan," "seek," "project," or "expect," "may," "will," "would," "could,"
"potential," "intend," or "should," the negative of these terms or similar
expressions. Forward-looking statements are based on management's current
beliefs and assumptions and on information currently available to the company.
However, these forward-looking statements are not a guarantee of the company's
performance, and you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties and other
variable circumstances, including negative worldwide economic conditions and
ongoing instability and volatility in the worldwide financial markets, ability
to obtain funding, ability to conduct current and future preclinical studies and
clinical trials, the timing, expense and uncertainty of regulatory approval,
reliance on third parties and collaboration partners, ability to commercialize
products, ability to manufacture any products, possible changes in current and
proposed legislation, regulations and governmental policies, pressures from
increasing competition and consolidation in the company's industry, the effects
of the COVID-19 pandemic on the company's business and results of operations,
ability to manage growth, reliance on key personnel, reliance on intellectual
property protection, ability to provide for patient safety, and fluctuations of
operating results due to the effect of exchange rates or other factors. Such
risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual results to
differ materially from those it thought would occur. The forward-looking
statements included in this press release are made only as of the date hereof.
The company does not undertake, and specifically declines, any obligation to
update any such statements or to publicly announce the results of any revisions
to any such statements to reflect future events or developments, except as
required by law.

For further information, please reference the company's reports and documents
filed with the U.S. Securities and Exchange Commission (SEC). You may get these
documents by visiting EDGAR on the SEC website at www.sec.gov.

SOURCE: CureVac

Topic:
Management Changes
Back to Newsroom
Drop us a line:
888.952.4446

Email:
Sales

Editorial

Content licensing



Copyright 2022 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms of
Service | Responsible Disclosure Guidelines
Chat with us, powered by LiveChat Please ensure Javascript is enabled for
purposes of website accessibility